Brief: Bioventus Inc - Plans Limited Release Of Talismann And Stimtrial In Some U.S. Markets In Q3
30/07/2025 12:34
July 30 (Reuters) - Bioventus Inc BVS.O: BIOVENTUS RECEIVES FDA 510(K) CLEARANCES FOR TWO NEXT-GENERATION PERIPHERAL NERVE STIMULATION PRODUCTS BIOVENTUS INC - PLANS LIMITED RELEASE OF TALISMANN AND STIMTRIAL IN SOME U.S. MARKETS IN Q3 Source text: ID:nGNX78Kwsk Further company coverage: BVS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bioventus
See all newsBioventus Inc. reports results for the quarter ended June 30 - Earnings Summary
Bioventus Q2 revenue misses estimates on surgical solutions decline
Bioventus Inc expected to post earnings of 22 cents a share - Earnings Preview
Bioventus Q1 revenue rises 7%, beats expectations
U.S. STOCKS ON THE MOVE -Erasca Inc, Regenxbio, Natgas stocks